Business Context and Reporting Period
This Form 8-K Current Report is filed by ETHZilla Corporation (formerly 180 Life Sciences Corp.) for the reporting period of August 22, 2025. The filing details the entry into a material definitive agreement regarding an "at-the-market" equity offering program.
Key Financial Metrics and Transaction Details
- Offering Capacity: The Company entered into an Amended and Restated Sales Agreement to sell up to $10.0 billion of common stock.
- Previous Proceeds: Under the Initial Sales Agreement (dated August 13, 2025), the Company sold 5,001,310 shares for aggregate gross proceeds of approximately $34.4 million.
- Agent Compensation: The sales agent, Clear Street LLC, is entitled to compensation of up to 3.0% of the gross sales price per share.
- Legal Expenses: The Company agreed to reimburse the Agent for legal expenses up to $75,000, plus ongoing legal costs.
- Recent Capital Activity: The Agent previously facilitated a private placement of approximately $425 million (Common Stock and pre-funded warrants) closing August 4, 2025, and senior secured convertible notes of $156.25 million closing August 8, 2025.
Note: This filing does not provide comprehensive financial statements, including revenue, net profit, operating cash flow, margins, or total debt levels.
Material Changes Versus Prior Period
The primary material change is the amendment of the sales agreement to increase the aggregate offering price capacity to $10.0 billion. Additionally, the Company has suspended the ability to make offers or sales under the initial prospectus filed on August 13, 2025, replacing it with the new Amended and Restated Sales Agreement and associated prospectus supplement.
Guidance, Outlook, and Risks
- Management Commentary: The Company retains the right to designate the maximum amount of stock to be sold and may instruct the Agent not to sell if prices fall below a designated level. Either party may terminate the agreement with 10 days' notice.
- Contingencies: Sales are subject to the terms of the Sales Agreement and applicable laws. The Company has no obligation to sell any shares.
- Risks: The filing includes standard disclaimers that the report does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful without registration.
Investor Verification Checklist
- Verify the current share count and potential dilution impact of a $10.0 billion offering capacity.
- Review the full text of the Amended and Restated Sales Agreement (Exhibit 1.1) for specific covenants and termination clauses.
- Confirm the status of the $425 million private placement and $156.25 million convertible notes mentioned as recent transactions.
- Check the Company's latest 10-K or 10-Q for actual revenue, cash flow, and debt metrics, as this 8-K does not contain them.